MSLE

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

TORONTO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL), a clinical-stage company developing potentially life-improving medicines to treat degenerative muscle diseases, today announced the formation of a Scientific Advisory Board (SAB) comprised of internationally recognized leaders in stem cell biology, regenerative medicine, neuroscience and small molecule chemistry who will help guide the company's long-term scientific exploration of regeneration, aging and neurodegenerative biology. "Much of my scientific career has been devoted to understanding how cellular polarity governs stem cell function and tissue regeneration," said Michael Rudnicki, OC, FRS

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

TORONTO, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL), a clinical-stage company developing potentially life-improving medicines to treat degenerative muscle diseases, today announced that management will participate in the following investor conferences in November. Guggenheim 3rd Annual Healthcare Innovation ConferenceDate: Monday, Nov. 9, 2026Fireside Chat: 9:30 a.m. ETLocation: Boston, MAWebcast Jefferies Global Healthcare ConferenceDate: Nov. 18-19, 2026Location: London, United Kingdom Members of the Satellos leadership team will be available for one-on-one investor meetings during both conferences. A replay of the fireside chat will be availabl

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

TORONTO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL), a clinical-stage drug development company developing potentially life-improving medicines to treat degenerative muscle diseases, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,747,245, entitled "AP2 associated kinase 1 inhibitors and uses thereof." The patent includes composition of matter claims covering forazapadin, Satellos’ lead clinical-stage drug candidate, as well as a broader class of AAK1 inhibitors and related compounds within the company's muscle regeneration platform. The composition of matter patent provides intellectual property prote

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

TORONTO, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced that enrollment has been completed for BASECAMP, the company’s Phase 2 clinical trial evaluating forazapadin for the treatment of Duchenne muscular dystrophy (DMD) in ambulatory boys 7 to 10 years of age. Forazapadin is an orally administered, small molecule drug candidate designed to restore muscle regeneration in people living with DMD, facioscapulohumeral muscular dystrophy (FSHD) and potentially other degenerative muscle diseases. "We are thrilled to announce th

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

TORONTO, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced four poster presentations at the 31st Annual Congress of the World Muscle Society (WMS). The Congress will take place in Hiroshima, Japan, from Sept. 29 to Oct. 3, 2026. Details of the scientific posters at WMS: Date & Time: Wednesday, Sept. 30, 5:15-6:15 p.m. JST Poster 2.74P: BASECAMP: A Phase 2a Dose Comparison and Exploratory Efficacy Study of Forazapadin (SAT-3247) in Ambulatory Boys with Duchenne Muscular Dystrophy Presenter: Anne M. Connolly, MD, Chief of t

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience (NASDAQ:MSLE, TSX:MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced the assignment of the International Nonproprietary Name (INN) "forazapadin" for the Company's orally administered, small molecule drug candidate designed to restore muscle regeneration that was previously known as SAT-3247. "As we continue to execute our clinical development strategies, this naming designation reflects the maturity of the program and supports its future development as we plan for regulatory submission and commercialization in Duchenne muscular dystrophy,

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced that management will participate in the following investor conferences in September. 2026 Cantor Global Healthcare ConferenceDate: Wednesday, September 9, 2026Presentation: 3:55 p.m. EDTLocation: New York, NYWebcast: here H.C. Wainwright 28th Annual Global Investment ConferenceDate: Wednesday, September 16, 2026 Fireside chat: 9 a.m. EDTLocation: New York, NYWebcast: here Members of the Satellos leadership team will be available for one-on-one investor meetings du

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

SUPPL - Satellos Bioscience Inc. (0001421642) (Filer)

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

Reported a reduction in muscle fat fraction by MRI along with increased total effort in all TRAILHEAD participants at month six, suggestive of muscle regenerationContinued favorable safety and tolerability profile, stable strength and improved quality of life reported in six-month follow-up data in TRAILHEAD Phase 2 adult DMD studyCompany remains on track to report clinical data from Phase 2 BASECAMP pediatric DMD study in Q4 2026Strong financial position with $61.8 million in cash, cash equivalents and short-term investments as of June 30, 2026, expected to provide runway through 2027SAT-3247 granted FDA Fast Track Designation for DMD TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Satellos B

F-X - Satellos Bioscience Inc. (0001421642) (Subject)

F-10 - Satellos Bioscience Inc. (0001421642) (Filer)

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

All four participants showed a decline in fat fraction as measured by MRI, with a mean improvement of 3.7% from 49.7% at TRAILHEAD baseline to 46.0% at month 6, suggesting improved muscle composition All four participants showed an increase in TE99C, a measure of maximum effort in upper limbs, with a mean improvement of approximately 34% from a baseline of 16.1 joules/kg to 21.6 joules/kg at TRAILHEAD month 6, suggesting enhanced upper limb activityNear doubling of handgrip strength measured during the 28-day CL-101 study maintained through month 6 of TRAILHEADMean creatine kinase (CK), a biomarker of muscle damage, declined 38% from baseline through month 6 of TRAILHEADSafety profile of SAT

6-K - Satellos Bioscience Inc. (0001421642) (Filer)

SAT-3247 has now received FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations for Duchenne muscular dystrophy ("Duchenne" or "DMD")Fast Track is designed to expedite the development/review of new drugs to treat serious or life-threatening conditions and fill unmet medical needsPhase 2 BASECAMP and TRAILHEAD studies ongoing in DMD with additional data expected in 2H 2026 TORONTO, June 29, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing novel therapies to treat degenerative muscle diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fas